Retour
Fourchette du Jour
232,24 €
236,00 €
Fourchette 52 Semaines
141,50 €
251,71 €
Volume
5 184 429
Moyenne 50J / 200J
234,14 €
/
194,58 €
Clôture Précédente
235,42 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 21,2 | 0,3 |
| P/B | 7,0 | 2,9 |
| ROE % | 35,0 | 3,7 |
| Net Margin % | 28,5 | 3,8 |
| Rev Growth 5Y % | 4,6 | 10,0 |
| D/E | 0,6 | 0,2 |
Objectif de Cours des Analystes
Hold
228,73 €
-2.8%
Low: 190,00 €
High: 265,00 €
P/E Prévisionnel
20,4
BPA Prévisionnel
11,56 €
Croissance BPA (est.)
+0,0%
CA Est.
100 B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
16,71 €
16,10 € – 17,19 €
|
130 B | 2 |
| FY2029 |
15,06 €
14,51 € – 15,49 €
|
120 B | 2 |
| FY2028 |
13,73 €
10,81 € – 16,03 €
|
110 B | 5 |
Insider Trading Activity
Buy ratio (90d)
0.0%
13 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
sell | 4 075 | 247,87 € | 1 010 070 € |
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
other | 8 150 | 115,67 € | — |
| Feb 20, 2026 |
Schmid Timothy
EVP, WW Chair, MedTech
|
sell | 1 322 | 245,66 € | 324 763 € |
| Feb 9, 2026 |
Broadhurst Vanessa
EVP, Global Corp Affairs
|
grant | 8 594 | — | — |
| Feb 9, 2026 |
Decker Robert J
VP Corporate Controller
|
grant | 2 741 | — | — |
| Feb 6, 2026 |
Mulholland Kristen
EVP, Chief HR Officer
|
other | 14 585 | 101,87 € | 1 946 404 € |
| Nov 26, 2025 |
MORIKIS JOHN G
Director
|
buy | 1 250 | 206,15 € | 257 688 € |
| Sep 9, 2025 |
Woods Eugene A.
Director
|
grant | 211 | 178,07 € | 37 573 € |
| Jul 17, 2025 |
REED JOHN C
EVP, Innovative Medicine, R&D
|
sell | 19 137 | 163,55 € | 3 129 830 € |
| Jun 10, 2025 |
HEWSON MARILLYN A
Director
|
grant | 322 | 155,23 € | 49 984 € |
| Apr 24, 2025 |
WEINBERGER MARK A
Director
|
grant | 1 316 | — | — |
| Apr 24, 2025 |
McClellan Mark B.
Director
|
grant | 1 316 | — | — |
| Apr 24, 2025 |
Woods Eugene A.
Director
|
grant | 1 316 | — | — |
Points Clés
Revenue grew 4,58% annually over 5 years — modest growth
Earnings grew 90,56% over the past year
ROE of 35,03% indicates high profitability
Net margin of 28,46% shows strong profitability
Generating 19,70B in free cash flow
PEG of 0,21 suggests growth is underpriced
Croissance
Revenue Growth (5Y)
4,58%
Revenue (1Y)6,05%
Earnings (1Y)90,56%
FCF Growth (3Y)3,90%
Qualité
Return on Equity
35,03%
ROIC14,83%
Net Margin28,46%
Op. Margin27,17%
Sécurité
Debt / Equity
0,59
Current Ratio1,03
Interest Coverage26,36
Valorisation
P/E Ratio
21,15
P/B Ratio6,95
EV/EBITDA23,25
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,05% | Revenue Growth (3Y) | 5,17% |
| Earnings Growth (1Y) | 90,56% | Earnings Growth (3Y) | -12,68% |
| Revenue Growth (5Y) | 4,58% | Earnings Growth (5Y) | 6,45% |
| Profitability | |||
| Revenue (TTM) | 94,19B | Net Income (TTM) | 26,80B |
| ROE | 35,03% | ROA | 13,46% |
| Gross Margin | 72,78% | Operating Margin | 27,17% |
| Net Margin | 28,46% | Free Cash Flow (TTM) | 19,70B |
| ROIC | 14,83% | FCF Growth (3Y) | 3,90% |
| Safety | |||
| Debt / Equity | 0,59 | Current Ratio | 1,03 |
| Interest Coverage | 26,36 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 21,15 | P/B Ratio | 6,95 |
| P/S Ratio | 6,02 | PEG Ratio | 0,21 |
| EV/EBITDA | 23,25 | Dividend Yield | 0,02% |
| Market Cap | 566,98B | Enterprise Value | 595,20B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94,19B | 88,82B | 85,16B | 79,99B | 78,74B |
| Net Income | 26,80B | 14,07B | 35,15B | 17,94B | 20,88B |
| EPS (Diluted) | 11,03 | 5,79 | 13,72 | 6,73 | 7,81 |
| Gross Profit | 68,56B | 61,35B | 58,61B | 55,39B | 55,34B |
| Operating Income | 25,60B | 22,15B | 23,41B | 21,01B | 20,94B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 199,21B | 180,10B | 167,56B | 187,38B | 182,02B |
| Total Liabilities | 117,67B | 108,61B | 98,78B | 110,57B | 108,00B |
| Shareholders' Equity | 81,54B | 71,49B | 68,77B | 76,80B | 74,02B |
| Total Debt | 47,93B | 36,63B | 29,33B | 39,64B | 33,75B |
| Cash & Equivalents | 19,71B | 24,11B | 21,86B | 12,89B | 14,49B |
| Current Assets | 55,62B | 55,89B | 53,50B | 55,29B | 60,98B |
| Current Liabilities | 54,13B | 50,32B | 46,28B | 55,80B | 45,23B |